Loyal Announces $45 Million Series B Financing to Continue Development of First FDA-Approved Dog Lifespan Extension Drug for Veterinary Use
[ad_1]
SAN FRANCISCO–(BUSINESS WIRE)– #funding–Loyal, a biotech company pioneering longevity drugs for dogs, announced it has successfully completed its Series B funding round of $45 million.
[ad_2]
